Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stenting And Thrombectomy Systems Fuel Neuro Device Market Growth

Executive Summary

Advances in distally protected carotid artery stenting systems and second-generation cerebral thrombectomy devices will help drive strong growth in the US neurointerventional device market over the next five years. The market, which includes endovascular devices for the treatment of cerebral aneurysms, arteriovenous malformations, stroke, and carotid artery disease, is projected to grow at a compound annual rate of 6.5%, and reach more than $846 million by 2018.

You may also be interested in...



FDA Clarifies Software Link In Abbott COVID-19 Lab Test Recall

The recall is related to the software’s mixing parameters, which may cause false positives if test samples contaminate each other.

Positive Signs For Valneva’s COVID-19 Vaccine, But Efficacy Data And Orders Still Lacking

Immunogenicity data from Valneva’s COV-COMPARE study are encouraging, but the inactivated vaccine will need proper efficacy data to gain a toehold in a crowded market.

Q3 Review: Editor’s Picks Of Scrip's Top Stories

From the latest COVID-19 advances to the emergence of game changer for heart failure, Scrip’s editor in chief Eleanor Malone reviews the big stories of the past three months. Safety issues around JAK inhibitors and AAV vector-based gene therapy were also to the fore, while biopharma financing continued apace.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT035827

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel